The combined deletion of S6K1 and Akt2 deteriorates glycemic control in a high-fat diet

Molecular and Cellular Biology

Volumn 32, Issue 19, 2012, Pages 4001-4011

  Treins, Caroline ^a,b   Alliouachene, Samira ^a,b   Hassouna, Rim ^a,b   Xie, Yun ^a,b   Birnbaum, Morris J ^c   Pende, Mario ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B BETA; SUBSTRATE S6 KINASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME INACTIVATION; GENE DELETION; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID DIET; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; DIET, HIGH-FAT; GENE DELETION; GLUCOSE; HYPERGLYCEMIA; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; WEIGHT GAIN;

MUS;

EID: 84868685585     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00514-12     Document Type: Article

References (40)

1. Aguilar V, et al. 2007. S6 kinase deletion suppresses muscle growth adaptations to nutrient availability by activating AMP kinase. Cell Metab. 5:476-487.
2. Alliouachene S, et al. 2008. Constitutively active Akt1 expression in mouse pancreas requires S6 kinase 1 for insulinoma formation. J. Clin. Invest. 118:3629 -3638.
3. Ayala JE, et al. 2010. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis. Model. Mech. 3:525-534.
4. Carnevalli LS, et al. 2010. S6K1 plays a critical role in early adipocyte differentiation. Dev. Cell 18:763-774.
5. Cho H, et al. 2001. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292: 1728-1731.
6. Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156 -159.
7. Danial NN, et al. 2008. Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat. Med. 14:144 -153.
8. Dibble CC, Asara JM, Manning BD. 2009. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol. Cell. Biol. 29:5657-5670.
9. Espeillac C, et al. 2011. S6 kinase 1 is required for rapamycin-sensitive liver proliferation after mouse hepatectomy. J. Clin. Invest. 121:2821- 2832.
10. Fraenkel M, et al. 2008. mTOR inhibition by rapamycin prevents betacell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57:945-957.
11. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. 2001. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl. Acad. Sci. U. S. A. 98:9666 -9670.
12. Harrington LS, et al. 2004. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166:213-223.
13. Harrison DE, et al. 2009. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460:392-395.
14. Holz MK, Blenis J. 2005. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J. Biol. Chem. 280:26089 -26093.
15. Houde VP, et al. 2010. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 59:1338 -1348.
16. Julien LA, Carriere A, Moreau J, Roux PP. 2010. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol. Cell. Biol. 30:908 -921.
17. Lamming DW, et al. 2012. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335: 1638-1643.
18. Laplante M, Sabatini DM. 2011. mTOR signaling. Cold Spring Harb. Perspect. Biol. 4:a011593. doi:10.1101/cshperspect.a011593.
19. Lu M, et al. 2012. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat. Med. 18:388 -395.
20. Lustig Y, et al. 2011. Separation of the gluconeogenic and mitochondrial functions of PGC-1{alpha} through S6 kinase. Genes Dev. 25:1232-1244.
21. Manning BD, Cantley LC. 2007. AKT/PKB signaling: navigating downstream. Cell 129:1261-1274.
22. Michael MD, et al. 2000. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell 6:87-97.
23. Ohanna M, et al. 2005. Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat. Cell Biol. 7:286 -294.
24. Pan KZ, et al. 2007. Inhibition of mRNA translation extends lifespan in Caenorhabditis elegans. Aging Cell 6:111-119.
25. Panasyuk G, et al. 2012. PPARgamma contributes to PKM2 and HK2 expression in fatty liver. Nat. Commun. 3:672.
26. Pende M, et al. 2000. Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature 408:994 -997.
27. Reznick RM, et al. 2007. Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. Cell Metab. 5:151- 156.
28. Ruvinsky I, et al. 2005. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev. 19:2199 -2211.
29. Saltiel AR, Kahn CR. 2001. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799-806.
30. Sarbassov DD, et al. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22:159 -168.
31. Selman C, et al. 2009. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 326:140 -144.
32. Shah OJ, Hunter T. 2006. Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. Mol. Cell. Biol. 26:6425- 6434.
33. Shima H, et al. 1998. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J. 17: 6649-6659.
34. Taniguchi CM, Emanuelli B, Kahn CR. 2006. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7:85-96.
35. Treins C, Warne PH, Magnuson MA, Pende M, Downward J. 2010. Rictor is a novel target of p70 S6 kinase-1. Oncogene 29:1003-1016.
36. Um SH, et al. 2004. Absence of S6K1 protects against age- and dietinduced obesity while enhancing insulin sensitivity. Nature 431:200 -205.
37. Vodenik B, Rovira J, Campistol JM. 2009. Mammalian target of rapamycin and diabetes: what does the current evidence tell us? Transplant. Proc. 41:S31-S38.
38. Yang SB, et al. 2011. Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. J. Mol. Med. (Berl). 90:575-585.
39. Yoon JC, et al. 2003. Suppression of beta cell energy metabolism and insulin release by PGC-1alpha. Dev. Cell 5:73- 83.
40. Zoncu R, Efeyan A, Sabatini DM. 2011. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12:21-35.